Цефиксим: клиническая фармакология и место в терапии инфекций урогенитального тракта
- Авторы: Рафальский ВВ1, Довгань ЕВ1, Деревицкий АВ1, Rafalsky VV2, Dovgan EV2, Derevitsky AV2
-
Учреждения:
- ГОУ ВПО Смоленская государственная медицинская академия Росздрава
- Выпуск: № 2 (2011)
- Страницы: 63-66
- Раздел: Статьи
- URL: https://journals.eco-vector.com/1728-2985/article/view/279080
- ID: 279080
Цитировать
Полный текст
Аннотация
Ключевые слова
Об авторах
В В Рафальский
ГОУ ВПО Смоленская государственная медицинская академия Росздрава
Email: v.rafalskiy@mail.ru
д-р мед. наук, проф.; проф. каф. управления и экономики фармации. Тел.: +7-910-787-1811; ГОУ ВПО Смоленская государственная медицинская академия Росздрава
Е В Довгань
ГОУ ВПО Смоленская государственная медицинская академия РосздраваГОУ ВПО Смоленская государственная медицинская академия Росздрава
А В Деревицкий
ГОУ ВПО Смоленская государственная медицинская академия РосздраваГОУ ВПО Смоленская государственная медицинская академия Росздрава
V V Rafalsky
E V Dovgan
A V Derevitsky
Список литературы
- Andes D. R., Craig W. A. Cephalosporins. In: Cohen J., Powderly W. G. et al., eds. Infectious diseases. London: Mosby; 2004. 294-307.
- Страчунский Л. С., Козлов С. Н. Современная антимикробная химиотерапия: Руководство для врачей. М.: Боргес; 2002.
- Bryskier A., Lebel M. Oral cephalosporins. In: Bryskier A. et al., eds. Antimicrobial agents: Antibacterials and antifungals. Washington: ASM Press; 2005. 222-235.
- Forti I. N. Review of oral cephalosporins. Basis for a rational choice. Medicina (B. Aires) 1994; 54: 439-458.
- Brogden R. N., Campoli-Richards D. M. Cefixime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential. Drugs 1989; 38: 524-550.
- Falkowski A., Look Z., Noguchi H., Silber B. Determination of cefixime in biological samples by reversed-phase high performance liquid chromatography. J. Chromatogr. 1987; 422: 145-152.
- Nakashima M., Uematsu T., Takiguchi Y., Kanamaru M. Phase 1 study of cefixime, a new oral cefalosporin. J. Clin. Pharmacol. 1987; 27: 425-431.
- Faulkner R. D., Yocobi L. A., Barone J. S. et al. Pharmacokinetic profile of cefixime in man. Pediatr. Infect. Dis. 1987; 6: 963-970.
- Faulkner R. D., Fernandez P., Lawrence G. et al. Absolute bioavailability of cefixime in men. J. Clin. Pharmacol. 1988; 28: 700-706.
- Healy D., Sahai J., Sterling L. et al. Influence of ar/mg-containing antacids on the pharmacokinetics of cefixime. Clin. Pharmacol. Ther. 1989; 45: 164.
- Bialer M., Tonelli A. P., Kantrowitz J. D., Yacobi A. Serum protein binding of a new oral cephalosporin, cl 284,635, in various species. Drug Metab. Disposit.: Biol. Fate Chem. 1986; 14: 132-136.
- Brittain D., Scully B, Hirose T., Neu H. The pharmacokinetics and bactericidal characreristics of oral cefixime. Clin. Pharmacol. Ther. 1985; 38: 590-594.
- Faulkner R. D., Bohaychuk W., Desjardings R. E. et al. Pharmacokinetics of cefixime after once-a-day and twice-a-day dosing to steady state. J. Clin. Pharmacol. 1987; 27: 807-812.
- Leroy A., Oser B., Grise P., Humbert G. Cefixime penetration in human renal parenchyma. Antimicrob. Agents Chemother. 1995; 39: 1240-1242.
- Saito A. Pharmacokinetic studies of cefixime. Chemotherapy 1985; 33: 190-203.
- Guay D., Meatherall R., Harding G., Brown G. Pharmacokinetics of cefixime in healthy subjects and patients with renal insufficiency. Antimicrob. Agents Chemother. 1986; 30: 485-490.
- Andreu A., Alos J., Gobernado M. et al. Etiology and antimicrobial susceptibility among uropathogens causing community-acquired lower urinary tract infections: A nationwide surveillance study. Enferm. Infecc. Microbiol. Clin. 2005; 1: 1-3.
- Hummers-Pradier E., Koch M., Ohse A. M. et al. Antibiotic resistance of urinary pathogens in female general practice patients. Scand. J. Infect. Dis. 2005; 37: 256-261.
- CDC: Update to cdc's sexually transmitted diseases treatment guidelines, 2006: Fluoroquinolones no longer recommended for treatment of gonococcal infections. Morbid. Mortal. Wkly Rep. 2007; 56: 332-336.
- Kubanova A., Frigo N., Kubanov A. et al. The Russian gonococcal antimicrobial susceptibility programme (ru-gasp) - national resistance prevalence in 2007 and 2008, and trends during 2005-2008. Euro Surveill. 2010; 15.
- ESSTI: Euro-gasp 2006 and 2007 summary report of gonorrhoeae antimicrobial susceptibility surveillance results; 2007.
- GISP: Gonococcal isolate surveillance project (gisp) annual report 2006. Atlanta, Georgia; 2008.
- Backhaus A., Tinzl J. Cefixim therapie bei patienten mit nachgewiesener gonorrhoe. Infection 1990; 18: 145-146.
- Kuhlwein A., Nies B. Efficacy and safety of a 400 mg single dose of oral cefixime in the treatment of uncomplicated gonorrhea. Advanc. Exp. Clin. Chemother. 1988; 1: 49-52.
- Hook E. W., Maccormack W. M., Martin D. et al. Comparison of single-dose oral grepafloxacin with cefixime for treatment of uncomplicated gonorrhea in men. Antimicrob. Agents Chemother. 1997; 41: 1843-1845.
- Tally F., Desjardins R., McCarthy E., Cartwright K. Safety profile of cefixime. Pediatr. Infect. Dis. 1987; 6: 976-980.
- Aronson J. K. et al. Meyler's side effects of drugs. In: The international encyclopedia of adverse drug reactions and interactions. 15-th ed. Oxford: Elsevier B. V., 2006.